Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hansol Chemical Co., Ltd. (014680.KS)
Seoul, KR
Hansol Chemical Co., Ltd., along with its subsidiaries, operates primarily in South Korea as a producer and supplier of a broad spectrum of chemicals. Its extensive fine chemical portfolio includes hydrogen peroxide, a versatile bleaching agent used across various sectors including semiconductors, LCDs, paper pulp, textiles, and environmental remediation. For industrial wastewater treatment, the company provides emulsion-type polyacrylamide and organic coagulants, and supplies retention agents, polyamine, and micro-capsules essential for papermaking. Its synthetic latex product line features HITEX, utilized in paper coatings, carpet backing, and construction; Bio-SBL, a grafting copolymer for paper surface sizing; HanCellymer, an aqua binder for lithium-ion batteries; and Hansphere, which improves the gloss and opacity of coated papers. Further fine chemical offerings include sodium dithionite/sodium hydrosulfite, a key bleaching agent for pulp, textiles, and leather, as well as benzoyl peroxide, which functions as both a polymerization initiator and a bleaching agent for the chemical and food sectors. Within its electronic materials division, Hansol Chemical offers UV-curable optical clear resins for tablet PCs and smartphones, along with conformal coatings designed to safeguard FPD panel circuits. Other electronic offerings include specialized cleaning solutions for coating equipment, black side sealing resins to prevent light leakage from OLED panels, and thermal interface materials crucial for FPCB chips. Additionally, the company develops thin film materials specifically for the semiconductor industry. Established in 1980, the firm operated as Hansol Chemience Co., Ltd. until its renaming to Hansol Chemical Co., Ltd. in March 2004. Its headquarters are situated in Seoul, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -10.89% | +1.40% | +0.87% | -8.21% | +22.83% | +21.04% | +126.78% | +39.66% | +23.88% | +288.37% | +3,486.42% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 9 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%+13.6% ★ Q1'26: +10.6% (vs Q1'25)
-
EPS growth Chemicals: +11.7%+21.8% ★ Q1'26: +14.0% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%+11.2% Q1'26: +10.0% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%+17.7% ★ Q1'26: +19.2% (vs Q1'25)
-
ROIC Chemicals: +3.4%+10.3% ★ Q1'26: +11.2% (vs Q1'25)
-
Share dilution Chemicals: +0.0%-1.5% ★ Q1'26: -0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×1.33× ★ Q1'26: 1.23× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 12 Rev. Ana. 12 EPS Ana. |
Dec 2027 12 Rev. Ana. 12 EPS Ana. |
Dec 2028 6 Rev. Ana. 7 EPS Ana. |
Dec 2029 11 Rev. Ana. 10 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
368.03B
est: 384.33B (-4.2%)
|
460.40B
est: 457.15B (+0.7%)
|
521.57B
est: 525.86B (-0.8%)
|
581.95B
est: 547.67B (+6.3%)
|
587.56B
est: 592.22B (-0.8%)
|
619.28B
est: 619.95B (-0.1%)
|
768.69B
est: 765.95B (+0.4%)
|
885.47B
est: 897.01B (-1.3%)
|
771.65B
est: 771.13B (+0.1%)
|
776.36B
est: 778.60B (-0.3%)
|
882.13B
est: 883.08B (-0.1%)
|
1.01T
917.37B – 1.07T
+14.3% YoY
|
1.16T
980.67B – 1.26T
+15.0% YoY
|
1.31T
1.15T – 1.41T
+13.2% YoY
|
1.52T
1.33T – 1.64T
+15.6% YoY
|
| EBITDA |
71.35B
est: 107.40B (-33.6%)
|
109.64B
est: 127.75B (-14.2%)
|
116.93B
est: 146.95B (-20.4%)
|
126.96B
est: 153.04B (-17.0%)
|
153.59B
est: 165.49B (-7.2%)
|
192.21B
est: 173.24B (+11.0%)
|
243.82B
est: 214.04B (+13.9%)
|
240.19B
est: 250.66B (-4.2%)
|
181.66B
est: 215.49B (-15.7%)
|
204.15B
est: 206.38B (-1.1%)
|
210.40B
est: 234.08B (-10.1%)
|
267.57B
243.17B – 284.09B
+14.3% YoY
|
307.64B
259.95B – 335.28B
+15.0% YoY
|
348.27B
304.71B – 374.97B
+13.2% YoY
|
402.69B
352.33B – 433.56B
+15.6% YoY
|
| EBIT |
50.03B
est: 83.79B (-40.3%)
|
82.76B
est: 99.66B (-17.0%)
|
84.22B
est: 114.64B (-26.5%)
|
100.42B
est: 119.40B (-15.9%)
|
116.29B
est: 129.11B (-9.9%)
|
154.10B
est: 135.15B (+14.0%)
|
201.12B
est: 166.98B (+20.4%)
|
190.97B
est: 195.55B (-2.3%)
|
128.69B
est: 168.11B (-23.5%)
|
153.10B
est: 158.56B (-3.4%)
|
156.24B
est: 179.84B (-13.1%)
|
205.57B
186.82B – 218.26B
+14.3% YoY
|
236.36B
199.71B – 257.59B
+15.0% YoY
|
267.57B
234.10B – 288.08B
+13.2% YoY
|
309.38B
270.69B – 333.10B
+15.6% YoY
|
| Net Income |
34.15B
est: 43.65B (-21.8%)
|
55.82B
est: 60.69B (-8.0%)
|
54.26B
est: 58.15B (-6.7%)
|
70.46B
est: 76.72B (-8.2%)
|
86.46B
est: 89.56B (-3.5%)
|
122.71B
est: 125.70B (-2.4%)
|
148.34B
est: 154.60B (-4.1%)
|
155.13B
est: 149.43B (+3.8%)
|
105.35B
est: 103.42B (+1.9%)
|
122.68B
est: 119.30B (+2.8%)
|
147.08B
est: 149.36B (-1.5%)
|
175.73B
147.57B – 194.39B
+17.7% YoY
|
216.81B
169.91B – 256.86B
+23.4% YoY
|
251.88B
210.93B – 276.98B
+16.2% YoY
|
333.24B
279.06B – 366.45B
+32.3% YoY
|
| SGA |
22.58B
est: 16.54B (+36.5%)
|
27.72B
est: 19.68B (+40.9%)
|
29.98B
est: 22.63B (+32.5%)
|
29.31B
est: 23.57B (+24.3%)
|
27.54B
est: 25.49B (+8.0%)
|
27.97B
est: 26.68B (+4.8%)
|
31.37B
est: 32.97B (-4.9%)
|
35.43B
est: 38.61B (-8.2%)
|
33.88B
est: 33.19B (+2.1%)
|
35.18B
est: 33.26B (+5.8%)
|
38.40B
est: 37.72B (+1.8%)
|
43.11B
39.18B – 45.78B
+14.3% YoY
|
49.57B
41.89B – 54.03B
+15.0% YoY
|
56.12B
49.10B – 60.42B
+13.2% YoY
|
64.89B
56.77B – 69.86B
+15.6% YoY
|
| EPS |
3,079.00
est: 3,882.75 (-20.7%)
|
5,034.00
est: 5,398.06 (-6.7%)
|
4,893.00
est: 5,172.27 (-5.4%)
|
6,354.00
est: 6,823.50 (-6.9%)
|
7,797.76
est: 7,966.14 (-2.1%)
|
10,375.00
est: 11,180.69 (-7.2%)
|
13,332.00
est: 13,751.18 (-3.0%)
|
14,099.00
est: 13,290.92 (+6.1%)
|
9,684.06
est: 9,198.56 (+5.3%)
|
10,979.00
est: 10,776.92 (+1.9%)
|
13,357.00
est: 13,492.38 (-1.0%)
|
15,874.59
13,330.21 – 17,560.30
+17.7% YoY
|
19,585.45
15,348.56 – 23,203.16
+23.4% YoY
|
22,753.52
19,053.83 – 25,021.07
+16.2% YoY
|
30,103.00
25,208.30 – 33,102.98
+32.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-14 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jang-An Han | Head of Management Support Division, Chief Financial Officer, CHRO, CSO & Full-Time Executive Directors | — | male |
| Jung-Woo Lee | MD & Head of Fine Chemical Sales Division | — | male |
| Won-Hwan Park | Chief Executive Officer & Director | — | male |
| Yeon-Ju Cho | Strategic Planning Manager & Full-Time Executive Directors | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 014680.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
